share_log

SenesTech | 8-K: Current report

SenesTech | 8-K: Current report

SenesTech | 8-K:重大事件
美股SEC公告 ·  2024/08/06 04:09

牛牛AI助理已提取核心訊息

SenesTech received a notification from Nasdaq on July 31, 2024, regarding non-compliance with audit committee requirements following the departure of Delphine François Chiavarini from the board and audit committee on July 11, 2024. The company no longer meets Nasdaq's requirement of having at least three independent directors on its audit committee.Nasdaq has granted SenesTech a cure period until the earlier of their next annual stockholders' meeting or July 11, 2025, to regain compliance. If the next annual meeting occurs before January 7, 2025, the company must demonstrate compliance by January 7, 2025. The notification has no immediate impact on SenesTech's Nasdaq Capital Market listing.The company is actively seeking a qualified independent board member who meets the audit committee criteria and intends to utilize the cure period to restore compliance. However, there is no guarantee of regaining or maintaining compliance with Nasdaq's continued listing requirements.
SenesTech received a notification from Nasdaq on July 31, 2024, regarding non-compliance with audit committee requirements following the departure of Delphine François Chiavarini from the board and audit committee on July 11, 2024. The company no longer meets Nasdaq's requirement of having at least three independent directors on its audit committee.Nasdaq has granted SenesTech a cure period until the earlier of their next annual stockholders' meeting or July 11, 2025, to regain compliance. If the next annual meeting occurs before January 7, 2025, the company must demonstrate compliance by January 7, 2025. The notification has no immediate impact on SenesTech's Nasdaq Capital Market listing.The company is actively seeking a qualified independent board member who meets the audit committee criteria and intends to utilize the cure period to restore compliance. However, there is no guarantee of regaining or maintaining compliance with Nasdaq's continued listing requirements.
SenesTech於2024年7月31日收到納斯達克的通知,因德爾芬·弗朗索瓦·基亞瓦里尼於2024年7月11日離開董事會和審計委員會,導致未能滿足審計委員會要求。公司不再符合納斯達克對審計委員會至少有三名獨立董事的要求。納斯達克已給予SenesTech一個治癒期,直至其下次年度股東大會或2025年7月11日中較早者,以恢復合規。如果下次年度會議在2025年1月7日之前舉行,公司必須在2025年1月7日前證明合規。該通知對SenesTech在納斯達克資本市場的上市沒有立即影響。公司正在積極尋求一位符合審計委員會標準的合格獨立董事,並打算利用治癒期恢復合規。然而,不能保證能夠恢復或維持與納斯達克持續上市要求的合規性。
SenesTech於2024年7月31日收到納斯達克的通知,因德爾芬·弗朗索瓦·基亞瓦里尼於2024年7月11日離開董事會和審計委員會,導致未能滿足審計委員會要求。公司不再符合納斯達克對審計委員會至少有三名獨立董事的要求。納斯達克已給予SenesTech一個治癒期,直至其下次年度股東大會或2025年7月11日中較早者,以恢復合規。如果下次年度會議在2025年1月7日之前舉行,公司必須在2025年1月7日前證明合規。該通知對SenesTech在納斯達克資本市場的上市沒有立即影響。公司正在積極尋求一位符合審計委員會標準的合格獨立董事,並打算利用治癒期恢復合規。然而,不能保證能夠恢復或維持與納斯達克持續上市要求的合規性。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。